0001209191-19-040368.txt : 20190702 0001209191-19-040368.hdr.sgml : 20190702 20190702165653 ACCESSION NUMBER: 0001209191-19-040368 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190701 FILED AS OF DATE: 20190702 DATE AS OF CHANGE: 20190702 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ALLEN LEE F MD PhD CENTRAL INDEX KEY: 0001408474 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38135 FILM NUMBER: 19938447 MAIL ADDRESS: STREET 1: C/O AMAG PHARMACEUTICALS, INC. STREET 2: 125 CAMBRIDGEPARK DRIVE, 6TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02140 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Dova Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001685071 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 813858961 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 240 LEIGH FARM ROAD CITY: DURHAM STATE: NC ZIP: 27707 BUSINESS PHONE: 919-806-4487 MAIL ADDRESS: STREET 1: 240 LEIGH FARM ROAD CITY: DURHAM STATE: NC ZIP: 27707 FORMER COMPANY: FORMER CONFORMED NAME: Dova Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20160919 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-07-01 0 0001685071 Dova Pharmaceuticals Inc. DOVA 0001408474 ALLEN LEE F MD PhD C/O DOVA PHARMACEUTICALS, INC. 240 LEIGH FARM ROAD, SUITE 245 DURHAM NC 27707 0 1 0 0 Chief Medical Officer Common Stock 2019-07-01 4 S 0 1957 14.19 D 10613 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person with the intent to cover withholding taxes in connection with the settlement of restricted stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.98 to $14.40 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. /s/ Mark Ballantyne, Attorney-in-Fact 2019-07-02